These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 8937971)

  • 1. In-vitro activity of a new quinolone, clinafloxacin, against clinical isolates of Corynebacterium species.
    Yagüe G; Herrera EA; Segovia M
    J Antimicrob Chemother; 1996 Oct; 38(4):740-2. PubMed ID: 8937971
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative in vitro activities of new quinolones against coryneform bacteria.
    Martínez-Martínez L; Suárez AI; Ortega MC; Perea EJ
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1439-41. PubMed ID: 8092851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Activity of new quinolones against clinical isolates of Corynebacterium species].
    Yagüe Guirao G; Martínez-Toldos MC; Mora Peris B; López Domínguez R; Romero Otero M; Muñoz Bellido JL; Segovia Hernández M
    Rev Esp Quimioter; 2000 Sep; 13(3):267-70. PubMed ID: 11086275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.
    Itokazu GS; Nathan C; Hariharan R; Kostman JR; Kabins SA; Weinstein RA
    Chemotherapy; 1996; 42(4):235-9. PubMed ID: 8804789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria.
    Shonekan D; Handwerger S; Mildvan D
    J Antimicrob Chemother; 1997 Mar; 39(3):405-9. PubMed ID: 9096191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antimicrobial activity of sparfloxacin, a new quinolone.
    Paradelis AG; Delidou K; Grigoriadou A; Salpigides G; Pangalis A
    Drugs; 1995; 49 Suppl 2():238-9. PubMed ID: 8549316
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro susceptibility of mycoplasmas to a new quinolone, BAY Y 3118.
    Renaudin H; Bébéar C
    Drugs; 1995; 49 Suppl 2():243-5. PubMed ID: 8549318
    [No Abstract]   [Full Text] [Related]  

  • 8. In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs.
    Cohen MA; Huband MD
    J Antimicrob Chemother; 1997 Aug; 40(2):308-9. PubMed ID: 9302005
    [No Abstract]   [Full Text] [Related]  

  • 9. In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents.
    Ford AS; Baltch AL; Smith RP; Ritz W
    J Antimicrob Chemother; 1993 Apr; 31(4):523-32. PubMed ID: 8390434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin.
    Cohen MA; Huband MD; Gage JW; Yoder SL; Roland GE; Gracheck SJ
    J Antimicrob Chemother; 1997 Aug; 40(2):205-11. PubMed ID: 9301985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative activity of three new fluoroquinolones.
    Coll R; Esteve M; Moros M; Parés J; Xicota MA
    Chemioterapia; 1987 Jun; 6(2 Suppl):152-3. PubMed ID: 3509374
    [No Abstract]   [Full Text] [Related]  

  • 12. In-vitro activity of three new fluoroquinolones and synergy with ansamycins against Mycobacterium leprae.
    Dhople AM; Ibanez MA
    J Antimicrob Chemother; 1993 Sep; 32(3):445-51. PubMed ID: 8262866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
    Cormican MG; Jones RN
    J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of lomefloxacin, a new difluorinated quinolone, against urinary bacterial isolates: comparison with enoxacin and ofloxacin.
    Azadian BS; Talboys CA; Roberts AP
    J Chemother; 1989 Jul; 1(4 Suppl):176-7. PubMed ID: 16312357
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones.
    Molinari G; Schito GC
    Drugs; 1995; 49 Suppl 2():222-5. PubMed ID: 8549310
    [No Abstract]   [Full Text] [Related]  

  • 16. Multidrug-Resistant Corynebacterium striatum Associated with Increased Use of Parenteral Antimicrobial Drugs.
    Hahn WO; Werth BJ; Butler-Wu SM; Rakita RM
    Emerg Infect Dis; 2016 Nov; 22(11):1908-14. PubMed ID: 27767926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.
    Roychoudhury S; Catrenich CE; McIntosh EJ; McKeever HD; Makin KM; Koenigs PM; Ledoussal B
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1115-20. PubMed ID: 11257024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A
    J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin, enrofloxacin and norfloxacin.
    Prescott JF; Yielding KM
    Can J Vet Res; 1990 Jan; 54(1):195-7. PubMed ID: 2306672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between mutations in the gyrA gene and quinolone resistance in clinical isolates of Corynebacterium striatum and Corynebacterium amycolatum.
    Sierra JM; Martinez-Martinez L; Vázquez F; Giralt E; Vila J
    Antimicrob Agents Chemother; 2005 May; 49(5):1714-9. PubMed ID: 15855486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.